Q3 2025 Royalty Pharma PLC Earnings Call Transcript

Nov 5, 2025 / 01:00 PM GMT

Release Date Price: €34.46 (+7.42%)

Transcript 10-Q8-K

Key Points

Positve

Royalty Pharma PLC (RPRX) reported an 11% growth in both portfolio and royalty receipts, driven by a strong diversified portfolio.
The company maintained strong returns with a return on invested capital of 15.7% and return on invested equity of 22.9% over the last 12 months.
Royalty Pharma PLC (RPRX) raised its full-year 2025 topline guidance for the third time this year, now expecting portfolio receipts between $3.2 billion and $3.25 billion.
The company has expanded its development stage pipeline to 17 therapies, with multiple pivotal readouts expected in the near future.
Royalty Pharma PLC (RPRX) has successfully executed significant transactions, including acquiring royalty interests in Amgen's lung cancer drug and a blockbuster therapy for TTR amyloidosis.

Negative

The company faces potential competition from follow-on therapies, such as El Nyon's Eucresin, which could impact future returns.
Royalty Pharma PLC (RPRX) anticipates minimal royalties from Promacta next year due to the launch of generics in the United States and Europe.
Interest payments are expected to increase in 2026, with anticipated interest paid between $350 million to $360 million.
Operating and professional costs are expected to be higher than usual due to one-time expenses related to internalization and other items.
The company acknowledges the risks and uncertainties associated with forward-looking statements and the potential for actual results to differ materially.

Refinitiv StreetEvents Event Transcript
P R E L I M I N A R Y V E R S I O N

RPRX.OQ - Royalty Pharma PLC
Q3 2025 Royalty Pharma PLC Earnings Call
Nov 05, 2025 / 01:00PM GMT

=====================
Conference Call Participants
=====================
* >>NOTE
* >>Transcription Start

=====================
Presentation
--------------------------------------------------------------------------------
>>NOTE [1]
--------------------------------------------------------------------------------

THIS TRANSCRIPT IS THE INITIAL PRELIMINARY VERSION WHICH LEVERAGES MACHINE LEARNING TECHNOLOGY. AS SUCH, PLEASE BE AWARE THERE MAY BE INACCURACIES IN THE TEXT DISPLAYED. FUTURE EDITED VERSIONS WILL BE REVIEWED FOR GREATER ACCURACY.

--------------------------------------------------------------------------------
>>Transcription Start, [2]
--------------------------------------------------------------------------------

Ladies and gentlemen, thank you for standing by.

Welcome to Royalty Farmer 3rd quarter earnings conference call.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.